Research programme: anti-Hsp90 antibodies - Biotecnol/Pharmis

Drug Profile

Research programme: anti-Hsp90 antibodies - Biotecnol/Pharmis

Latest Information Update: 14 Jun 2012

Price : $50

At a glance

  • Originator Biotecnol SA; Pharmis Biofarmaceutica
  • Class Antibodies
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Jun 2012 Preclinical development is ongoing Portugal
  • 30 May 2007 Preclinical trials in Cancer in Portugal (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top